Plasma orexin a, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis

International Clinical Psychopharmacology

Volumn 25, Issue 3, 2010, Pages 165-171

  Basoglu, Cengiz ^a   Oner, Ozgur ^b   Gunes, Cengiz ^c   Semiz, Umit B ^a   Ates, Alpay M ^a   Algul, Ayhan ^a   Ebrinc, Servet ^a   Cetin, Mesut ^a   Ozcan, Omer ^a   Ipcioglu, Osman ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b DR SAMI ULUS CHILDREN S HOSPITAL   (Turkey)

^c Diyarbakr Military Hospital   (Turkey)

Author keywords

Agouti related protein; Cholecystokinin; First episode psychosis; Ghrelin; Leptin; Olanzapine; Orexin A; Visfatin

Indexed keywords

AGOUTI PROTEIN; CHOLECYSTOKININ; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROPEPTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OLANZAPINE; OREXIN A; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MENTAL PATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; RATING SCALE; SCORING SYSTEM; SEROTONINERGIC SYSTEM; SYMPTOM; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

AGOUTI-RELATED PROTEIN; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY MASS INDEX; CHOLECYSTOKININ; DISEASE PROGRESSION; GHRELIN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEPTIN; LIPIDS; MALE; NEUROPEPTIDES; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; TIME FACTORS; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 77950955451     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3283377850     Document Type: Article

References (51)

1. Adam JA, Menheere PPCA, van Dielen FMH, Soeters PB, Buurman WA, Greve JWM (2002). Decreased plasma orexin-A levels in obese individuals. Int J Obes 26:274-276.
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999). Antipychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696.
3. Anubhuti SA (2006). Role of neuropeptides in appetite regulation and obesity: a review. Neuropeptides 40:375-401.
4. Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas JA (2008). Comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophr Res 104:1-12.
5. Atmaca M, Kuloglu M, Tezcan E, Ustundag B (2003). Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 64:598-604. (Pubitemid 36618291)
6. Baranowska B, Woliñ ska-Witort E, Martyñska L, Chmielowska M, Baranowska-Bik A (2005). Plasma orexin A, orexin B, leptin, neuropeptide Y (NPY) and insulin in obese women. Neuro Endocrinol Lett 26:628.
7. Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, Garć?a-Portilla MP, Fernández I, et al. (2003). Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 62:77-88.
8. Brixner DI, Said Q, Corey-Lisle PK, Tuomari AV, L'italien GJ, Stockdale W, et al. (2006). Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother 40:626-632.
9. Cai XJ, Widdowson PS, Harrold J, Wilson S, Buckingham RE, Arch JR, et al. (2008). Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes 48:2132-2137.
10. Davoodi N, Kalinichev M, Korneev SA, Clifton PG (2009). Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. Psychopharmacology 203:693-702.
11. English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP (2002). Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 87:2984.
12. Esen-Danaci A, Sarandöl A, Taneli F, Yurtsever F, Ozlen N (2008). Effects of second generation antipsychotics on leptin and ghrelin. Prog Neuropsycho-pharmacol Biol Psychiatry 32:1434-1438.
13. Fadel J, Bubser M, Deutch AY (2002). Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci 22:6742-6746.
14. Fukuhara A, Matsuda M (2005). Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426-430. (Pubitemid 40139988)
15. Graham KA, Cho H, Brownley KA, Harp JB (2008). Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. Schizophr Res 101:287-294.
16. Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, et al.; HGDH Study Group (2006). Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 86:234-243.
17. Harris GC, Aston-Jones G (2006). Arousal and reward: a dichotomy in orexin function. Trends Neurosci 29:571-577.
18. Himmerich H, Fulda S, Künzel HE, Pfennig A, Dzaja A, Cummings DE, et al. (2005). Ghrelin plasma levels during psychopharmacological treatment. Neuropsychobiology 52:11-16.
19. Hosojima H, Togo T, Odawara T, Hasegawa K, Miura S, Kato Y, et al. (2006). Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 20:75-79.
20. Jin H, Meyer JM, Mudaliar S, Jeste DV (2008). Impact of atypical therapy on leptin, ghrelin and adiponectin. Schizophr Res 100:70-85.
21. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085-1097.
22. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
23. Kinon BJ, Basson BR, Gilmore JA, Toleffson GD (2001). Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62:92-100.
24. Komaki G, Matsumoto Y, Nishikata H, Kawaki K, Nozaki T, Taki M, et al. (2001). Orexin-A and leptin change inversely in fasting non-obese subjects. Eur J Endocrinol 144:654-1651
25. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, et al.; HGDH Study Group (2005). Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 62:361-370.
26. Lopez M, Tovar S, Vazquez MJ, Williams LM, Dieguez C (2007). Peripheral tissue-brain interactions in the regulation of food intake. Proc Nut Soc 66:131-155.
27. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis J, et al. (2004). Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161:1334-1349.
28. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19-32.
29. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al. (2007). Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week-comparison. Am J Psychiatry 164:1050-1060.
30. Monda M, Viggiano A, Viggiano A, Mondola A, Viggiano E, Messina G, et al. (2008). Olanzapine blocks the sympathetic and hyperthermic reactions due to cerebral injection of orexin A. Peptides 29:120-126.
31. Murashita M, Kusumi I, Inoue T, Takahashi Y, Hosoda H, Kangawa K, et al. (2005). Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 30:106-110.
32. Palik E, Birkás KD, Faludi G, Karádi I, Cseh K (2005). Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 68 (Suppl 1): S60-S64.
33. Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, et al. (2007). A 12 week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine or risperidone. J Clin Psychiatry 68:1733-1740.
34. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez-Jimenez M, Pelayo-Teran JM, et al. (2008a). Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophr Res 99:13-22.
35. Perez-Iglesias R, Vazquez-Barquero JL, Amado JA, Berja A, Garcia-Unzueta MT, Pelayo-Terán JM, et al. (2008b). Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. J Clin Psychopharmacol 28:289-295.
36. Perez-Iglesias R, Mata I, Pelayo-Teran JM, Amado JA, Garcia-Unzueta MT, Berja A, et al. (2009). Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-nä?ve population. Schizophr Res 107:115-121. [Epub 2008 November 6].
37. Quarta D, Di Francesco C, Melotto S, Mangiarini L, Heidbreder C, Hedou G (2009). Systemic administration of ghrelin increases extracellular dopamine in the shell but not the core subdivision of the nucleus accumbens. Neurochem Int 54:89-94.
38. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, et al. (2002). Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 41:337-343.
39. Richards AA, Hickman IJ, Wang AY, Jones AL, Newell F, Mowry BJ, et al. (2006). Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum. J Clin Psychopharmacol 26:232-237.
40. Saddichha S, Ameen S, Akhtar S (2008). Predictors of antipsychotic- induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol 28:27-31.
41. Stefanidis A, Verty AAN, Allen AM, Owens NC, Cowley MA, Oldfield BJ (2008). The role of thermogenesis in drug-induced weight gain. Obesity 17:16-24.
42. Strassnig M, Miewald J, Keshavan M, Ganguli R (2007). Weight gain in newly diagnosed first-episode patients and healthy comparisons: one year analysis. Schizophr Res 93:90-98.
43. Tanaka K, Morinobu S, Ichimura M, Asakawa A, Inui A, Hosoda H, et al. (2008). Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 32:1527-1532.
44. Thakore JH (2005). Metabolic syndrome and schizophrenia. Br J Psychiatry 186:455-456.
45. Theisen FM, Gebhardt S, Brömel T, Otto B, Heldwein W, Heinzel-Gutenbrunner M, et al. (2005). A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm 112:1411-1416.
46. Togo T, Hasegawa K, Miura S, Hosojima H, Kojima K, Shoji M, et al. (2004). Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology (Berl) 172:230-232.
47. Valassi E, Scacchi M, Cavagnini F (2008). Neuroendocrine control of food intake. Nut Met Cardiovascular Dis 18:158-168.
48. Wallingford NM, Sinnayah P, Bymaster FP, Gadde KM, Krishnan RK, McKinney AA, et al. (2008). Zonisamide prevents olanzapine associated hyperphagia, weight gain, and elevated blood glucose in rats. Neuropsycho-pharmacology 33:2922-2933.
49. Weiden PJ, Mackell JA, McDonnell DD (2004). Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 66:51-57.
50. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, Tang JS (2006). Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 186:572-578.
51. Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, et al. (2005). Course and predictors of weight gain in people with first-episode psychosis-treated with olanzapine or haloperidol. Br J Psychiatry 187:537-543.